AGEBOX Inc. recalled 665 bottles of iKids-Growth capsules on October 28, 2025, due to undeclared ibutamoren. The product was marketed without an approved NDA/ANDA. Consumers should stop using the product immediately and contact Agebox for guidance.
Marketed Without an Approved NDA/ANDA: presence of undeclared ibutamoren
Consumers and healthcare providers should stop using this product immediately. Contact Agebox or your healthcare provider for guidance. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Agebox iKids-Growth (Day Formula) capsules in 60-count bottles. The affected lot numbers are 23101201 exp 09/2026, 24080801 exp 07/2027, and 25020701 exp 01/2028. The product was sold through Agebox.com and Amazon.
The product contains undeclared ibutamoren, a substance that may pose health risks. This recall is classified as Class II, indicating a potential for serious health consequences.
There have been no reported incidents or injuries associated with this recall at this time. Consumers are urged to be cautious regarding the undeclared ingredient.
Stop using the product immediately. Contact Agebox or your healthcare provider for further guidance. Refunds are available by reaching out via email.
For more information, consumers can visit the Agebox website or contact the company via email. Additional details are available on the FDA's recall page.
Get instant alerts for recalls that affect you. Free forever.
AvKARE recalled Amantadine HCl capsules on February 13, 2026, due to failed dissolution specifications. The recall affects the 100 mg capsules, which may not dissolve properly. Consumers should stop using this product and contact their healthcare provider immediately.
Slate Run Pharmaceuticals recalled Eptifibatide Injection on February 12, 2026. The recall affects all lots of the 75 mg/100 mL vial due to incorrect dosing information. Healthcare providers and consumers must stop using the product immediately.
LEO Pharma Inc. recalled 11,407 units of Adbry injection on February 10, 2026. The recall stems from a lack of assurance of sterility due to particulate matter identified as wool fiber. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Hitachi Ltd. recalled one unit of its Proton Beam Therapy System on February 6, 2026 due to a software anomaly. The issue may result in positional discrepancies during patient treatment. The recall affects distribution in Texas and Washington D.C.
Hitachi recalled its Proton Beam Therapy System on February 6, 2026, due to a software anomaly that may result in positional discrepancies. The recall affects one unit distributed in Texas and Washington D.C. Healthcare providers and patients must stop using the device immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.